



International Cancer Screening Network Meeting

Rotterdam, The Netherlands
June 2–4, 2015

Tuesday, June 2, 2015

8:00 a.m. – 5:00 p.m. **Registration (Jurriaanse Hall)**

8:00 a.m. – 12:00 p.m. **Poster setup for all 3 days (Arcadis Zaal)**

9:00 a.m. – 10:30 a.m. **Concurrent Sessions**

A) Cervical Cancer Screening International Interest Group—*open meeting for all participants* (Van Cappellen Zaal)

Leads: *Paul Doria-Rose and Mona Saraiya*

Presentations:

- The screen-and-treat strategy as an alternative screening for cervical cancer in remote regions of Colombia—*Carolina Wiesner*
- Cervix cancer screening: HPV DNA testing versus visual methods in a limited resource setting—*Malliga Subramanian*
- Small scale screening: Working beside communities to create a sustainable solution to cervical cancer screening in the Peruvian Amazon—*Geordan Shannon*

B) Colorectal Cancer Screening International Interest Group—*open meeting for all participants* (Jurriaanse Zaal)

Leads: *Carrie Klabunde and Linda Rabeneck*

Discussant: *Douglas Corley*

Presentations:

- Colorectal cancer screening for safety net practices: Strategies and opportunities to STOP colon cancer in priority populations—*Gloria Coronado*
- Comparing measures to prevent imminent waiting lists for colonoscopy in fecal immunochemical test-based screening programs—*Iris Lansdorp-Vogelaar*
- The New Hampshire Colonoscopy Registry: A comprehensive evidence base supporting individualized colorectal cancer screening—*Lynn Butterly*
- Impact of colonoscopy quality on the effectiveness and costs of colorectal cancer screening: A modeling study—*Reinier Meester*

C) Prostate Cancer Screening Interest Group

Moderator: *Harry de Koning*

10:30 a.m. – 11:00 a.m. **Break (Jurriaanse Foyer)**

- 11:00 a.m. – 12:30 p.m. **Concurrent Sessions**
- A) International Test Sets for Evaluating Interpretive Performance (Van Cappellen Zaal)
Leads: *Bonnie Yankaskas and Mireille Broeders*
- 11:00 a.m. – 12:00 p.m.—*open meeting for all participants*
12:00 p.m. – 12:30 p.m.—*closed meeting for work group members only*
- B) International Interest Group on the Interface Between Primary Care and Cancer Screening—*open meeting for all participants* (Jurriaanse Zaal)
Leads: *David Weller and Stephen Taplin*
Presentation:
- The role of primary care in cancer screening: International comparison study by Ca-PRI and the International Cancer Screening Network—*David Weller*
- 12:30 p.m. – 2:00 p.m. **Lunch (Jurriaanse Foyer)**
- 2:00 p.m. – 4:30 p.m. **Concurrent Workshops**
- A) Workshop on Microsimulation Modeling for Cancer Screening—*limited capacity* (Education Centre Room 22 [Entrance Fe or Ff building in Erasmus MC])
Leads: *Ann Zauber, Iris Lansdorp-Vogelaar, Nicolien T. van Ravesteyn, and Kevin ten Haaf*
- B) Workshop on Overdiagnosis in Cancer Screening—*open meeting for all participants* (Jurriaanse Zaal)
Leads: *Ruth Etzioni and Nereo Segnan*
Presentations:
- Overdiagnosis due to mammography screening: Estimates from South Australia—*Kerri Beckmann*
 - Reducing overdiagnosis by polygenic risk-stratified screening: Findings from the Finnish arm of the European randomised study—*Nora Pashayan*
 - Minimizing the harm of mammographic overdiagnosis—*Lawrence Paszat*
- C) Workshop on Implementation Sciences Research for Cancer Screening in Low and Middle Income Countries
Leads: *Sudha Sivaram, Pamela Marcus, Hillary Topazian, and Cindy Vinson*
- 4:30 p.m. – 6:00 p.m. **Poster Session (Arcadis Zaal)**
Moderator: *Jessica Chubak*
- 6:00 p.m. – 6:30 p.m. **Break (Jurriaanse Foyer)**
- 6:30 p.m. – 8:00 p.m. **Reception at Rotterdam Town Hall**
- 8:00 p.m. **Adjournment**

Wednesday, June 3, 2015

- 8:00 a.m. – 5:00 p.m. **Registration (Jurriaanse Hall)**
- 9:00 a.m. – 10:15 a.m. **Welcome and Keynote Presentations (Jurriaanse Zaal)**
- 9:00 a.m. – 9:15 a.m. **Welcoming Remarks from Co-Chairs**
Carrie Klabunde, National Institutes of Health, Bethesda, MD, USA
Harry de Koning, Erasmus Medical Center, Rotterdam, The Netherlands
- 9:15 a.m. – 9:45 a.m. **Keynote 1: The Impact of DNA Damage on Cancer and Aging**
Jan Hoeijmakers, Erasmus Medical Center, Rotterdam, The Netherlands
- 9:45 a.m. – 10:15 a.m. **Keynote 2: Ovarian Cancer Screening: Vain Hope or Imminent Reality**
Ian Jacobs, University of Manchester, Manchester, United Kingdom
- 10:15 a.m. – 10:45 a.m. **Break (Jurriaanse Foyer)**
- 10:45 a.m. – 12:15 p.m. **Session 1: Individualized Screening (Jurriaanse Zaal)**
Moderator: Jessica Chubak
- 10:45 a.m. – 11:00 a.m. A framework for developing risk-based screening guidelines: “Equal management of equal risks”—Hormuzd Katki
- 11:00 a.m. – 11:15 a.m. The Nordic Information for Action eScience Center: Advancing individualized screening in the Nordic countries—Karin Sundström
- 11:15 a.m. – 11:30 a.m. Role of adherence in optimizing mammography screening—Oguzhan Alagoz
- 11:30 a.m. – 11:45 a.m. Exploration of the benefit of risk-stratified colorectal cancer screening based on common genetic variants: Current status and future potential—Steffie Naber
- 11:45 a.m. – 12:00 p.m. Do men and women need to be screened differently with the fecal immunochemical test? A cost-effectiveness analysis—Miriam van der Meulen
- 12:00 p.m. – 12:15 p.m. Q & A Discussion
- 12:15 p.m. – 1:30 p.m. **Lunch (Jurriaanse Foyer)**
- 1:30 p.m. – 3:00 p.m. **Session 2: Implementation and Lessons Learned from Organized Programs (Jurriaanse Zaal)**
Moderator: Robert Smith
- 1:30 p.m. – 1:45 p.m. Comparison of cancer screening participation in the UK and the USA—Sue Moss

- 1:45 p.m. – 2:00 p.m. Biting the bullet: From biennial PAP tests to 5 yearly primary HPV screening: Renewal of Australia’s national cervical screening program—*Tracey Bessell*
- 2:00 p.m. – 2:15 p.m. Cervical cancer screening in Europe: Quality assurance and organization of programs—*Miriam Elfström*
- 2:15 p.m. – 2:30 p.m. International comparison of recommendations and requirements for mammography screening program readers to start and continue reading screening mammograms—*Berta Geller*
- 2:30 p.m. – 2:45 p.m. Does community-based integrated cancer screening lead to mortality reduction?—*Sam Li-Sheng Chen*
- 2:45 p.m. – 3:00 p.m. Q & A Discussion
- 3:00 p.m. – 3:30 p.m. **Break (Jurriaanse Foyer)**
- 3:30 p.m. – 5:00 p.m. **Panel Discussion of Lung and Prostate Cancer Screening (Jurriaanse Zaal)**
Moderator: *Harry de Koning*
Speakers: *Michael Lefevre, University of Missouri, Columbia, MO, USA*
Matthijs Oudkerk, University of Groningen, Groningen, The Netherlands
Jonas Hugosson, University of Gothenburg, Gothenburg, Sweden
- 5:00 p.m. – 6:00 p.m. **Session 3: Optimizing Benefits and Minimizing Harms—Part 1 (Jurriaanse Zaal)**
Moderator: *Jean-Luc Bulliard*
- 5:00 p.m. – 5:15 p.m. Mammography screening performance in the Dutch Breast Cancer Screening Programme: Interval cancers 2004 to 2009—*Jacques Fracheboud*
- 5:15 p.m. – 5:30 p.m. Breast cancer screening using tomosynthesis in combination with digital mammography compared to digital mammography alone within the PROSPR consortium—*Elisabeth Beaber*
- 5:30 p.m. – 5:45 p.m. Quantifying benefits and harms in cervical cancer screening: A decision-analytic approach—*Kine Pedersen*
- 5:45 p.m. – 6:00 p.m. Q & A Discussion
- 6:00 p.m. **Adjournment**
- 7:30 p.m. – 10:30 p.m. **Group Dinner at the Euromast**

Thursday, June 4, 2015

- 8:00 a.m. – 2:00 p.m. **Registration (Jurriaanse Hall)**
- 8:30 a.m. – 10:00 a.m. **Session 3: Optimizing Benefits and Minimizing Harms—Part 2 (Jurriaanse Zaal)**
Moderator: *Paul Doria-Rose*
- 8:30 a.m. – 8:45 a.m. The impact of overdiagnosis on the selection of efficient lung cancer screening strategies using low-dose computed tomography—*Summer Han*
- 8:45 a.m. – 9:00 a.m. The (cost-)effectiveness of lung cancer screening in Ontario, Canada—*Kevin ten Haaf*
- 9:00 a.m. – 9:15 a.m. Effectiveness of quantitative fecal immunochemical testing in reducing colorectal cancer mortality from the One Million Taiwanese Screening Program—*Han-Mo Chiu*
- 9:15 a.m. – 9:30 a.m. PSA testing for prostate cancer: Would organised screening be cost-effective compared to current practice? Evidence from Ireland—*Linda Sharp*
- 9:30 a.m. – 9:45 a.m. Likely effect of adding flexible sigmoidoscopy to the English NHS Bowel Cancer Screening Programme: Impact on colorectal cancer cases and deaths—*Sandra Geurts*
- 9:45 a.m. – 10:00 a.m. Q & A Discussion
- 10:00 a.m. – 10:30 a.m. **Break (Jurriaanse Foyer)**
- 10:30 a.m. – 11:30 a.m. **Late Breaking Abstract/Rapid Fire Presentation Session (Jurriaanse Zaal)**
Moderator: *Erica Breslau*
- The CoheaHr consortium: Comparing health services interventions for the prevention of HPV-related cancer – *Johannes Berkhof*
 - Globalization of Population-based Cancer Screening in Asia through International Asian Conference on Cancer Screening (IACCS) – *Hsiu-Hsi Chen*
 - EU-TOPIA – *Iris Lansdorp-Vogelaar*
 - HPV-based home test for non-attenders using an option strategy and modern technology-based communication – a pilot implementation in Denmark – *Janni Uyen Hoa Lam*
 - Stage-based mortality impact of cervical screening – *Peter Sasieni*
 - Identifying Women With Dense Breasts at High Risk for Interval Cancer – *Diana Miglioretti*
 - Interval Cancers and Effectiveness of Colorectal Cancer Screening Program in the Basque Country – *Eunate Arana Arri*

11:30 a.m. – 12:30 p.m.

**Panel Discussion of Breast Cancer Screening in Light of New Evidence
(Jurriaanse Zaal)**

Moderator: *Stephen Taplin*

Speakers:

- From historic to recent data: Considerations when moving from RCTs to evidence from modern service screening—*Mireille Broeders, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands*
- *IARC Handbooks of Cancer Prevention, Volume 15: Breast Cancer Screening*—*Beatrice Lauby-Secretan, International Agency for Research on Cancer, Lyon, France*
- The effect of population-based mammography screening in Dutch municipalities on breast cancer mortality: Long-term follow up—*Valerie Sankatsing, Erasmus Medical Center, Rotterdam, The Netherlands*

12:30 p.m. – 2:00 p.m.	Lunch (Jurriaanse Foyer)
2:00 p.m. – 3:30 p.m. (Jurriaanse Zaal)	Session 4: Screening in Low-Resource Countries and Populations
	<i>Moderators: Larry von Karsa and Mona Saraiya</i>
2:00 p.m. – 2:15 p.m.	Clinical trial to implementation: Cost and benefits of scaling up cervical cancer screening in India— <i>Sujha Subramanian</i>
2:15 p.m. – 2:30 p.m.	HPV DNA test as primary screening technology for cervical cancer screening in rural China: A real-world feasibility study— <i>Yuqian Zhao</i>
2:30 p.m. – 2:45 p.m.	Use of cold coagulation as an alternative treatment modality in a “see and treat” programme of cervical screening in rural Malawi— <i>Christine Campbell</i>
2:45 p.m. – 3:00 p.m.	Tailoring South Korea’s breast cancer screening strategy to its incidence peak found in women aged 40 to 50— <i>Jeroen van den Broek</i>
3:00 p.m. – 3:15 p.m.	Assessment of colorectal cancer screening knowledge, attitudes, and practices among Brazilian health care providers— <i>Douglas Perin</i>
3:15 p.m. – 3:30 p.m.	Q & A Discussion
3:30 p.m. – 4:00 p.m.	Break (Jurriaanse Foyer)
4:00 p.m. – 4:45 p.m. (Jurriaanse Zaal)	Session 5: Risk Assessment and Informed Decision Making
	<i>Moderator: David Weller</i>
4:00 p.m. – 4:15 p.m.	Personalized risk assessment for breast cancer, discussion of risk, and intention to use screening— <i>Jennifer Haas</i>
4:15 p.m. – 4:30 p.m.	Baseline fecal hemoglobin concentration as a risk factor of interval cancers after colonoscopy in a fecal immunochemical test-based population colorectal cancer screening program— <i>Sherry Yueh-Hsia Chiu</i>
4:30 p.m. – 4:45 p.m.	Q & A Discussion
4:45 p.m. – 5:00 p.m.	Wrap Up and Plans for the 2018 ICSN Meeting (Jurriaanse Zaal)